Referenze

 

1. Ruemmele FM. Pediatric Crohn’s disease-coming of age ? Curr Opin Gastroenterol 2010;26:332-6.

2. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-39.

3. Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr. 2010;50:27.

4. Swidsinki A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.

5. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1999;338:771-4

6. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.

7. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599-603.

8. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptative immunity in the intestin tract. Science 2005;307:731-4.

9. Guandalini S. Use of Lactobacillus-GG in paediatric Crohn’s disease. Dig Liver Dis 2002;34 Suppl 2:S63-5.

10. Langlands SJ, Hopkins MJ, Coleman M et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004;53:1610-6.

11. Sokol H, Seksik P, Furet JP et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183-9.

12. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006;55:205-211.

13. Mangin I, Bonnet R, Seksik P, et al. Molecular inventory of faecal microflora in patients with Crohn’s disease. FEMS microbiology ecology 2004;50:25-36.

14. Seksik P. Microbiote intestinal et MICI. Gastroentérologie Clinique et Biologique. 2010;34:48-55.

15. Schwiertz A, Jacobi M, Frick JS et al. Microbiota in pediatric inflammatory bowel disease. J Pediatr 2010;157:240-4.

16. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731-6.

17. Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fiber on methotrexateinduced enterocolitis in rats. Gastroenterology 1996;111:334-44.

18. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.

19. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.

20. Huynh HQ, De Bruyn J, Guan L et al. Probiotic preparation VSL#3 induces remission in children with mild tomoderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009;15:760-768.

21. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-443.

22. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacilus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflam Bowel Dis 2005;11:883-9.

23. Sheil B, McCarthy J, O’Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004 53:694-700.

24. Rachmilewitz D, Katakura K, Karmeli F,et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.

25. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin- 10. Science 2000;289:1352-5.

26. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin- 10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754-9.

 

 

 

<< Torna alla Home